Prostate cancer is a malignant tumor of the prostate gland, usually adenocarcinoma, and is one of the most common cancers in men.
Data from the WINGMEN Phase 0 trial of Xentuzumab in prostate cancer is now available on Oxford's Translational Data Platform, which holds data from over 1,100 participants across five studies.
New research highlights strategies to overcome cancer drug resistance: a triple-drug AML combination, a breast cancer resistance target, evolutionary treatment switching, DNA damage mechanisms, and sildenafil's anti-metastatic potential.
Merck & Co. is bolstering its oncology pipeline with acquisitions like Terns Pharmaceuticals and Cidara Therapeutics, while Keytruda remains the key growth driver. It expects Keytruda peak sales of $35 billion by 2028 and aims to launch 20 new drugs by 2030.
Pilot genetic testing at ESMO Breast Cancer 2026 found inherited variants in 8.6% of breast and 10.1% of ovarian cancer survivors. A systematic review linked mammographic surveillance to a 50% lower mortality risk.
Phase 3 PROTEUS: perioperative apalutamide plus ADT met both dual primary endpoints in high-risk localized prostate cancer, raising pCR/MRD rates to 8.9% vs 1.0% and cutting metastasis or death risk by 20%.
Candel initiated the Phase 3 AURORA trial of aglatimagene in NSCLC and plans a Q4 2026 BLA in localized prostate cancer, with a potential 2027 launch. The company also appointed a Chief Commercial Officer.
A recent global analysis shows oncology dominates clinical trial activity in 2025, while Phase II attrition rates dropped to 26%—the lowest in four years. The US remains the leader in investigator sites, but China is the fastest-growing market. Obesity research is poised to break into the top five most-studied diseases.
A large clinical trial found that adding apalutamide to hormone therapy before and after prostate cancer surgery improves outcomes for high-risk patients. NHS England will roll out SABR radiotherapy requiring only five sessions, and new ctDNA and robotic biopsy technologies are advancing prostate cancer care.
UNM Comprehensive Cancer Center installs MRI-LINAC, enabling real-time tumor tracking and adaptive radiation therapy. The system has treated 10 patients and improves precision, reducing damage to healthy tissue.
Amgen detailed its T-cell engager and precision therapy strategy at Citi's 2026 summit. GT Biopharma, Onco-Innovations, Oncotelic, and Samsung Biologics also advanced AI and organoid platforms in drug development.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07768917 |
Training on Systemic and Organ Spec. PM in PC |
NOT_YET_RECRUITING | NA |
| NCT07766603 |
Preoperative Breathing Exercise Training and Postoperative Delirium After Robotic Radical Prostatectomy |
NOT_YET_RECRUITING | NA |
| NCT07765940 |
Safety and Preliminary Diagnostic Performance of [⁶⁴Cu]Cu-RAX301 in Prostate Cancer |
NOT_YET_RECRUITING | PHASE1/PHASE2 |
| NCT07762911 |
Evaluation of an MRI-based Prostate Cancer Screening Program (VISIONING): 5-Year Follow-up Round (VISIONING III) |
RECRUITING | NA |
| NCT07756593 |
Sipuleucel-T (Sip-T) in Combination With N-803 in Metastatic Androgen Pathway Modulation Resistant (mAPMR) Prostate Cancer |
NOT_YET_RECRUITING | PHASE1 |
| NCT07754929 |
E-Mergir: A Digital Psychosexual Intervention for the Promotion of Mental and Sexual Health of Prostate Cancer Survivors |
RECRUITING | NA |
| NCT07753356 |
VALIDATION OF FUSION CEMEP SCORE FOR OMITTING SYSTEMATIC PROSTATE BIOPSY |
NOT_YET_RECRUITING | |
| NCT07751133 |
Evaluating Hormone Therapy to Achieve Optimal Doses in Metastatic Prostate Cancer |
NOT_YET_RECRUITING | PHASE3 |
| NCT07747272 |
Nerve-SPARing Robotic Prostatectomy: The Impact of Patient Baseline Profiles on Erectile Function |
RECRUITING | |
| NCT07745361 |
Study of Oral MRT-2359 With Apalutamide in Prostate Cancer |
RECRUITING | PHASE2 |
